Existing PDAC risk prediction models for patients with NOD show moderate discrimination, however, substantial heterogeneity, limited independent external validation, incomplete calibration reporting, and inconsistent assessment of clinical utility constrain their immediate clinical translation.
Dan Li, Nan-Nan Zhang, Rui Li et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.